Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at
Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – November 25, 2019
Telix Pharmaceuticals Limited (ASX: TLX) has today announced that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which hosted over 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.

The Jefferies 2019 London Healthcare Conference featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, Australia, China and Japan. Dr. Behrenbruch presented on Telix’s advanced clinical-stage portfolio of Molecularly Targeted Radiation (MTR) programs.

Dr. Behrenbruch’s presentation can be viewed at the Jefferies London Healthcare Conference website at http://www.wsw.com/webcast/jeff123/tlx/

To read the full media release click here.